miRNA discovery & development platform

MicroRNAs (miRNAs) are small (19–23 nucleotides) noncoding RNA molecules regulating gene expression profile. The importance of miRNAs has been recognized by the 2024 Nobel Prize, as miRNA type oligonucleotides represent an innovative area of multitarget drug development that are capable of modulating complex molecular network of diseases that cannot be targeted by conventional single-target drugs, such as e.g. ischemia/reperfusion injury and several types of oncology disease (Bereczki Z et al, Br J Pharmacol, 2025; PMID: 39293936).

microRNAs – multitarget medicines
Pharmahungary Group, a group of innovative R&D companies developed miRNAtarget (www.mirnatarget.com), a bioinformatics tool based on miRNA-mRNA molecular networks analysis, enabling the discovery and development of miRNAs. PH offers miRNA-mRNA target analysis for free for academic use. Utilizing miRNAtarget, PH offers drug discovery and development service for miRNA drug candidates (including off-target analysis) for industry partners for various therapeutic indications including cardiovascular, metabolic, and oncology.

Using its unique miRNA discovery and development platform, PH discovered and patented cardioprotective micro-RNAs (termed protectomiRs) around 4 different miRNA families. The lead candidate miR-125b* is in small animal proof-of-concept stage. PH is currently seeking co-development partners and raising capital for further development of miRNA drug candidates. Pharmahungary is uniquely positioned to further develop these drug candidates due to its more than 2 decades of experience as a preclinical R&D service provider that has been involved in more than 350 different drug-development projects.

Uniting its miRNA drug discovery and development platform, Pharmahungary Group is offering a new complex service globally:

• disease-agnostic miRNA drug discovery service
• efficacy testing of miRNAs and other RNA drugs from in vitro to large animal proof-of-concept studies focusing on cardiovascular, metabolic, and oncology diseases

Pharmahungary is seeking for:

• miRNA co-development partners (especially focusing on innovative miRNA chemistry and delivery system)
• investors
• clients for innovative R&D services from in vitro to in vivo efficacy models including custom-designed co-morbidity models and large animal models.

Contact us:
Pharmahungary Group,
Graphisoft Park, Záhony-Street 7,
Budapest, H-1031, Hungary,
European Union
businessdevelopment@pharmahungary.com

This advertorial was originally published in European Biotechnology Magazine Winter 2025.